Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

Van Nieuwenhuysen, Els; Vergote, Ignace; Randall, Leslie M.; Tromp, Jacqueline; Lorusso, Domenica; O’Cearbhaill, Roisin E.; Boere, Ingrid; Pisano, Carmela; Sanchez, Luis Manso; Banerjee, Susana; Collins, Dearbhaile C.; Zikán, Michal; Mathews, Cara; Kümmel, Jan; Melichar, Bohuslav; Jackson, Amanda L.; Madsen, Kristine; Gennigens, Christine; Ottevanger, Nelleke; Ghamande, Sharad; Salutari, Vanda; Baurain, Jean-Francois; Reyners, Anna K.L.; Chisamore, Michael; Conte, Umberto; Windfeld, Kristian; Geiger, Melissa; Hansen, Henrik; Denys, Hannelore; Cibula, David; Oaknin, Ana; Van Gorp, Toon; Monk, Bradley J.

doi:10.1016/j.ygyno.2026.02.008

Article (Scientific journals)

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

Van Nieuwenhuysen, Els; Vergote, Ignace; Randall, Leslie M. et al.

2026 • In Gynecologic Oncology, 207, p. 3-13

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/344097

DOI
10.1016/j.ygyno.2026.02.008

PubMed
42000372

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer- 5-year results from the innovaTV 205_ENGOT-cx8_GOG-3024 study.pdf

Publisher postprint (453.61 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Oncology

Author, co-author :

Van Nieuwenhuysen, Els

Vergote, Ignace

Randall, Leslie M.

Tromp, Jacqueline

Lorusso, Domenica

O’Cearbhaill, Roisin E.

Boere, Ingrid

Pisano, Carmela

Sanchez, Luis Manso

Banerjee, Susana

More authors (23 more)

Language :

English

Title :

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

Publication date :

April 2026

Journal title :

Gynecologic Oncology

ISSN :

0090-8258

eISSN :

1095-6859

Publisher :

Elsevier BV

Volume :

207

Pages :

3-13

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S0090825826008012?httpAccept=text/xml

Funders :

Pfizer
NCI - National Cancer Institute
Genmab
NIH - National Institutes of Health

Available on ORBi :

since 17 April 2026

Statistics

Number of views

27 (1 by ULiège)

Number of downloads

15 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Yamagami, W., Nagase, S., Takahashi, F., Ino, K., Hachisuga, T., Aoki, D., et al. Clinical statistics of gynecologic cancers in Japan. J. Gynecol. Oncol., 28, 2017, e32.
Gennigens, C., Jerusalem, G., Lapaille, L., De Cuypere, M., Streel, S., Kridelka, F., et al. Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open., 7, 2022, 100579.
Abu-Rustum, N.R., Campos, S.M., Amarnath, S., Arend, R., Barber, E., Bradley, K., et al. Cervical cancer, version 2.2026. J. Natl. Compr. Canc. Netw. 23 (2025), 549–573.
Lorusso, D., Colombo, N., Dubot, C., Cáceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Ann. Oncol. 36 (2025), 65–75.
Oaknin, A., Gladieff, L., Martínez-García, J., Villacampa, G., Takekuma, M., De Giorgi, U., et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 403 (2024), 31–43.
De Giorgi, U., Mansi, L., Martinez-Garcia, J., Villacampa, G., Takekuma, M., Lindemann, K., et al. Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC) [abstract 10O]. ESMO Open, 10(Suppl. 5), 2025, 105140.
Cocco, E., Varughese, J., Buza, N., Bellone, S., Glasgow, M., Bellone, M., et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer, 11, 2011, 263.
de Bono, J.S., Concin, N., Hong, D.S., Thistlethwaite, F.C., Machiels, J.P., Arkenau, H.T., et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 20 (2019), 383–393.
Tivdak [package insert]. Bothell, WA, and Plainsboro, NJ: Seagen Inc. and Genmab US Inc.; 2024.
Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N. Engl. J. Med. 391 (2024), 44–55.
Vergote, I., Van Nieuwenhuysen, E., O'Cearbhaill, R., Westermann, A., Lorusso, D., Ghamande, S., et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. J. Clin. Oncol. 41 (2023), 5536–5549.
Oaknin, A., Monk, B.J., de Melo, A.C., Kim, H.S., Kim, Y.M., Lisyanskaya, A.S., et al. Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase III EMPOWER-cervical 1/GOG-3016/ENGOT-cx9 trial. Eur. J. Cancer, 216, 2025, 115146.
Colombo, N., Dubot, C., Lorusso, D., Caceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385 (2021), 1856–1867.
Tewari, K.S., Sill, M.W., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240). Lancet 390 (2017), 1654–1663.